Literature DB >> 10535754

Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited.

G Natarajan1, R Malathi, E Holler.   

Abstract

The molecular mechanism of carboplatin [cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II)] activation is still unresolved. We studied the binding of carboplatin to calf thymus DNA in the presence of thiourea, glutathione, and human breast cancer MCF-7 cell cytoplasmic extracts by measurement of DNA-dependent ethidium bromide fluorescence and atomic absorption spectroscopy. After a 96-hr period of reaction, the decrease in the DNA-dependent fluorescence yield of ethidium bromide due to the formation of platinum (Pt)-DNA adducts increased significantly in the presence of thiourea (6-fold) and glutathione (3- to 4-fold) as compared to the controls in the absence of the nucleophiles. There was also a marked elevation in the levels of platinum incorporated into DNA, measured by atomic absorption spectroscopy (2- to 3-fold and 5- to 7-fold for thiourea and glutathione, respectively). More remarkably, the Pt-DNA adducts formed in the presence of cytoplasmic extracts of MCF-7 human breast cancer cells also showed similar results in a dose-related fashion. Carboplatin, therefore, displayed a characteristic increase in DNA binding/damaging in the presence of the very same S-containing nucleophiles that showed the expected quenching effects in the case of cisplatin [cis-diamminedichloroplatinum (II)]. We propose a nucleophile-facilitated release of the active species of carboplatin prior to binding with DNA.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10535754     DOI: 10.1016/s0006-2952(99)00250-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Antitumor carboplatin is more toxic in tumor cells when photoactivated: enhanced DNA binding.

Authors:  Jarmila Mlcouskova; Jana Stepankova; Viktor Brabec
Journal:  J Biol Inorg Chem       Date:  2012-05-26       Impact factor: 3.358

2.  Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors.

Authors:  Benjamin Miron; Elizabeth Handorf; Kevin Zarrabi; Matthew R Zibelman; Fern Anari; Pooja Ghatalia; Elizabeth R Plimack; Daniel M Geynisman
Journal:  Urol Oncol       Date:  2022-07-02       Impact factor: 2.954

Review 3.  Cisplatin in cancer therapy: molecular mechanisms of action.

Authors:  Shaloam Dasari; Paul Bernard Tchounwou
Journal:  Eur J Pharmacol       Date:  2014-07-21       Impact factor: 4.432

4.  Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients.

Authors:  Shahbal B Kangarloo; Suman B Gangopadhyay; Rachel M Syme; Johannes E A Wolff; Stefan Glück
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

5.  How can the cisplatin analogs with different amine act on DNA during cancer treatment theoretically?

Authors:  Arezo Rahiminezhad; Mahboube Eslami Moghadam; Adeleh Divsalar; A Wahid Mesbah
Journal:  J Mol Model       Date:  2021-12-07       Impact factor: 1.810

6.  DNA-Platinum Thin Films for Use in Chemoradiation Therapy Studies.

Authors:  Mohammad Rezaee; Elahe Alizadeh; Darel Hunting; Léon Sanche
Journal:  Bioinorg Chem Appl       Date:  2011-10-02       Impact factor: 7.778

Review 7.  Trial Watch: Peptide-based anticancer vaccines.

Authors:  Jonathan Pol; Norma Bloy; Aitziber Buqué; Alexander Eggermont; Isabelle Cremer; Catherine Sautès-Fridman; Jérôme Galon; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-01-09       Impact factor: 8.110

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.